Data room / Run 1, stage 2: the nine cross-examinations

Insurance and actuarial

Cross-examination, written by the insurance and actuarial reviewer, 4,384 words, about 19 min to read

run-1/reviews/crossexam-insurance-actuarial.md Open the file as written

CROSS-EXAMINATION — INSURANCE & ACTUARIAL REVIEWER (Stage 2)

Reviewer: credentialed actuary (FSA/MAAA-equivalent), insurance-regulatory and insurance-asset-management lens. Date: 2026-08-01. Stage 1 position re-adopted from insurance-actuarial.md, subject to the two corrections conceded below. Materials for this stage: all eight peer Stage 1 reports plus crossexam-investor.md (which disputes two of my Stage 1 findings); spec consulted for parameter spot-checks only.

Method note: every number below was recomputed this session in Python (amortization of the spec's $350K/30yr first mortgage, sale-exit recoveries, reserve coverage, discharge-adjusted expected loss, licensed-carrier premium, and homeowner APR-equivalents under a repriced ratchet). Where I concede, I show the corrected model; where I rebut, I show the arithmetic. Claim tags: SETTLED LAW / LIKELY INTERPRETATION / STATE-DEPENDENT / AMBIGUOUS / SPECULATIVE.

Summary of my responses to the investor's challenges, up front:

  • Their Dispute 1 (my "-45% recovery" claim): PARTIAL CONCESSION — conceded on the arithmetic and the headline claim; rebutted only on the scope of their worst-case vintage. My Shield kill gets stronger, and my one pro-product mitigation is withdrawn as stated.
  • Their Dispute 2 (omitted Chapter 7 discharge channel): FULL CONCESSION, with the actuarial re-quantification they asked for. My "6-18x overpriced" claim is revised down to ~1.5-4.5x; my tail-underfunding claim worsens.

================================================================================

PART 1 — DISPUTES (including responses to the investor's two disputes of my work)

R1. Response to investor Dispute 1 — "distressed sales almost never breach

the floor / recovery robust at −45%": PARTIAL CONCESSION (mostly concede).

What I concede. The investor's arithmetic is correct and reproduces exactly on the spec's standard parameters ($625K enrollment, $350K first mortgage, 30yr at a deep-lock 3.5%):

  • Mortgage balance after 84 months: $297,656 (their figure, confirmed).
  • Sale at −45% from enrollment, fully deployed vintage: sale $343,750; net of 7% costs $319,688; escrow to investor $22,031 against a $126,000 claim — recovery 0.175x. Their 0.17x is right. An 83% principal loss on a sale.
  • With a 20% pre-peak runup: recovery 0.68x (84-month mortgage age) to 0.82x (their 108-month variant). Either way, breached.
  • My Stage 1 "$158K escrow" figure requires a sale price of ~$490K at trough, i.e., a +42.5% two-year pre-peak runup — an extreme-percentile vintage presented as representative. The number cannot be produced from the spec's parameters on any defensible path. I withdraw it.

What actually survives, precisely stated. The corrected result is a knife-edge, not robustness: for a fully deployed 84-month vintage, the breakeven drawdown from enrollment is −27.1% (sale $455,544 clears $126,000 after costs and payoff). The 2007-2012 national trough (−26.5%) clears the floor by $3,563 — a 1.03x recovery with zero margin. My Stage 1 generalized that knife-edge to −45%, which was wrong: at sand-state severity the floor is breached catastrophically in sale exits, exactly as the investor computes. The honest statement is: the escrow-first structure protects capital in national-scale corrections and fails as a second ~full-severity loss channel in concentrated/sand-state corrections — which is the design case, since spec Section 17 targets concentrated markets for $100M+ books.

The narrow rebuttal (scope only, and it does not save my claim). The investor's 0.17x vintage — fully deployed AND facing −45% from its own enrollment value — requires enrollment ≥84 months before the peak with zero interim appreciation. Under the pause mechanism, peak-adjacent vintages are only partially deployed (their own internal-consistency note anticipates this, and they are right that my Stage 1 could not have both full deployment and a working pause — I concede that inconsistency). The corrected per-vintage picture at a −45% trough:

Vintage (months pre-peak) Deployed at pause+run-on Escrow available Recovery
0 ~$9,000 $22,031 1.00x
12 ~$27,000 $22,031 0.82x
24 ~$45,000 $22,031 0.49x
84+ (fully deployed, no runup) $126,000 $22,031 0.17x

So the book-level severity of the distressed-sale channel is a blend of 0.17x-1.0x recoveries by vintage, not uniformly 0.17x — but the blend is far worse than my Stage 1's ~35% implied severity. This is a correction of their extreme, not a defense of mine.

Knock-on corrections to my Stage 1 tables (concession quantified). Re-running my sand-state stress row (12% foreclosure + 20% distressed sale, $63.2M deployed basis, $5.69M reserve) with corrected distressed-sale severity of ~65-85% instead of ~35%:

Scenario Shortfall Reserve coverage
Stage 1 as published $12.0M 0.47x
Corrected sale severity $17.1M 0.33x
+ 2% Ch. 7 discharge (see R2) $18.3M 0.31x
+ 4% discharge (post-roadmap contagion) $19.6M 0.29x

Consequences, stated plainly: (a) my Equity Shield kill strengthens — reserve coverage in the design-case tail falls from "less than half" to "less than a third"; (b) my Stage 1 verdict bullet 3 ("escrow-first 1.0x recovery is genuinely robust in sale exits even at −45%") is WITHDRAWN as stated and replaced by the breakeven-drawdown formulation above; (c) the investor's Stage 1 C5 (no spread anywhere to absorb any credit loss) stands against my corrected numbers, as they claimed.

R2. Response to investor Dispute 2 — omitted Chapter 7 discharge channel:

FULL CONCESSION, with the actuarial re-quantification.

Estate 4.1 establishes — and I adopt their tag, SETTLED LAW (11 U.S.C. §101(5); Johnson v. Home State Bank, 501 U.S. 78 (1991)) — that as drafted ("not a lien," spec §34) the position is a dischargeable claim in Chapter 7: a sale-independent, ~100%-severity loss channel my Stage 1 decomposition ("floor loss = foreclosure rate × deployed capital") omitted. Red-team F2/M4 correctly adds that the channel is industrializable and correlated (published-roadmap contagion through an organized consumer-bankruptcy bar) in a book deliberately selected for equity-rich, cash-poor households.

Re-quantification on the $63.2M deployed basis, normal decade:

Loss basis Expected loss Fee multiple ($5.69-9.0M collected)
Foreclosure only (my Stage 1) ~$0.5M 12-19x
+ 3% cumulative discharge (~0.3%/yr hazard) ~$2.0M 2.9-4.5x
+ 7% cumulative discharge (post-roadmap, ~0.7%/yr) ~$4.2M 1.4-2.2x

Revisions to my Stage 1: the "fee is 6-18x expected loss" overpricing claim is overstated as the investor argued — corrected range ~1.5-4.5x. The tail-underfunding claim is correspondingly understated (see the corrected coverage table in R1). Same verdict, corrected decomposition — and I accept their point that the decomposition, not the verdict, is what a Tier 2 buyer prices from.

One addition from my domain that strengthens both my kills: the discharge channel is an elective, non-fortuitous loss — it is triggered by the insured population's own legal strategy, not by a fortuitous event. No licensed carrier writes elective legal-strategy losses as an insurable peril (fortuity is a foundational insurability requirement — LIKELY INTERPRETATION as applied here). So the discharge channel is uninsurable in principle, not merely underpriced: it defeats even the licensed-carrier rebuild of Equity Shield (see FX-C) and independently degrades any Tier 2 price, because the buyer inherits a loss channel that scales with publicity about the product itself.

D3. Investor Stage 1, A5 — "the fee accumulates ~2.2% of peak deployed

capital over 7 years — an order of magnitude short of a credible 1.0x

floor": OVERSTATED (minor).

A credible portfolio floor does not require 100% of deployed capital; it requires capital sized to a 1-in-200-type tail, which I sized in Stage 1 Finding 1.3 at 6-12% of deployed. Against that standard, 2.2% is 3-5x short, not an order of magnitude. The conclusion (the fee cannot fund the floor) is right; the benchmark is wrong, and it matters because the correct benchmark defines what an honest fix costs (~$6-12M day-one capital on $100M, or a 140-230bps premium — FX-C), which is expensive-but-finite rather than absurd. Precision here protects the kill from an easy sponsor rebuttal.

D4. Securities/consumer-finance, Verdict pt. 1 — the core product's

problems are "expensive but solvable compliance builds": DISPUTED on

insurance-capital grounds (distinct from the investor's Dispute 5).

The investor disputed this on funding capacity (the platform cannot pay for the build). My dispute is independent and survives even if the build is funded: the salvage premise assumes that once legal/compliance work is done, the two-tier structure functions. It does not, because the Tier 2 exit fails on capital arithmetic that no compliance spend changes: Schedule BA treatment with ~30% (or 45% residual) RBC charges nets an insurer bond-like returns for unrated novel risk (my 3.1 — LIKELY INTERPRETATION on the exact factor); the rated wrapper cannot exist before the mid-2030s (my 3.2); and first-fund seasoning is statistically incapable of supporting pricing (my 4.4). "Solvable" describes the securities architecture, not the buyer base. A legally compliant fund with no exit buyer is compliant and dead. Sec-cf's fix-before-launch on the core implicitly assumes a financeable two-tier structure; that assumption is contradicted by findings sec-cf itself defers to ("actuarial solvency is deferred to the insurance-actuarial reviewer").

D5. Retail P7 and red-team H7 — "positions priced off mortality and

mobility tables" / "sold to an insurer that profits when she dies":

DISPUTED as to mechanism (the harm is real; the buyer is not).

Both reports treat insurer purchase-and-pricing as the operative predation mechanism. My 4.1/4.4 show the premise fails: there are no credible mobility tables conditional on rate regimes, and no insurer clears RBC on this paper — the "priced off mortality and mobility tables" pitch is the sponsor's marketing, and repeating it as the harm mechanism concedes the sponsor's most contested factual claim (that the paper is institutionally priceable at all). The realistic version of the harm is red-team M2's orphaned-holder covenant weaponization: positions land not with regulated insurers but with whatever unregulated yield vehicle will take unpriceable paper at a deep discount — a holder with worse incentives and no prudential oversight. That is a more damaging finding, and it is the one the evidence supports. Retail and red-team should restate the harm accordingly; as written, the findings are vulnerable to the rebuttal "no insurer would ever buy this" — which happens to be my own conclusion.

D6. Product-operator, Verdict — "if the sponsor funds a real servicing

entity... this becomes an operable product": DISPUTED as to the implied

viability conclusion.

Operability is necessary, not sufficient. The operator's own fix (6.1: a 25-75bps servicing strip priced into the Tier 2 exit) lowers the Tier 2 bid below my Stage 1 fair-value range (0.69-1.10x deployed vs. the 1.41x the marketed IRR requires) — the fix that makes the product operable makes the exit gap wider. A $4-7M operations build attached to a 20-30-year-duration book with no LP base (investor C1/C4, my 3.3) and no exit buyer (my 3.1-3.2, 4.3) is a well-run machine for originating unfinanceable assets. The operator's "not a kill" verdict evaluates the machine; the machine's output has no buyer. (The investor's DC-3 flags the mirror conflict with tax; I add the capital-markets leg.)

Verified / adopted, not disputed (mandated cross-checks)

  • Investor crossexam Dispute 1 arithmetic: reproduced exactly (0.175x; their 0.82x runup variant reproduces at a 108-month mortgage age). Adopted.
  • Estate 4.1: adopted in full with their SETTLED LAW tag; it now sits inside my loss decomposition (R2).
  • Operator 1.4 (pause-frequency math — ~50% of a flat-market book printing below enrollment on AVM noise): directionally checked and plausible; with a median-unbiased AVM and zero drift, ~half of quarterly prints fall below enrollment by symmetry. If anything their 30-50% is conservative. Adopted — and note it feeds my FX-E analysis.
  • Investor B2/B4/B5 grids: cross-verified in Stage 1 (they verified my 112K figure; I verify their framework). No change.
  • Red-team F11/M3 (wash-trade risk on the first Tier 2 sale): adopted; it is the fraud-mode complement of my 4.3 (no rational arm's-length bid at the required price implies the first observed "market price" is suspect by construction).

================================================================================

PART 2 — PEER FIXES THAT CREATE NEW PROBLEMS IN MY DOMAIN

FX-A. True-lien recording (title Required-fix 1; estate Required-fix 1):

does NOT change RBC treatment or unlock insurance buyers, and adds costs

the Tier 2 price inherits.

The title and estate reviewers are right that lien status fixes enforcement, priority, and bankruptcy survival. But the implied benefit for the insurance-capital thesis is illusory:

  • Statutory accounting/RBC is unchanged. NAIC Schedule B (mortgage loans) requires an obligation with defined payment terms; an appreciation- contingent, zero-coupon, no-maturity claim does not become a "mortgage loan" for schedule purposes by being secured by a deed of trust. It remains a Schedule BA "other invested asset" at ~30% C-1 (or 45% if swept into the residual-tranche factor). LIKELY INTERPRETATION. The RBC arithmetic in my 3.1 — the finding that kills the insurer-demand thesis — survives the fix entirely.
  • It can make the asset worse for an insurer. Lien + the 1.0x senior repayment strengthens SAM/debt recharacterization (tax D-1, Rev. Rul. 83-51); under CPDI treatment the holder accrues phantom ordinary interest (tax D-4(a)) — statutory income volatility with no cash, on a decades-long hold. Insurers price phantom-income assets punitively. LIKELY INTERPRETATION (adopting tax's chain).
  • Recording/doc-stamp taxes (tax S-2, title 1.3 — STATE-DEPENDENT) become per-deal costs of an indeterminate secured amount; several states force a stated maximum claim, which caps the ratchet on the face of the recorded instrument — a term Tier 2 buyers would price as a hard payoff ceiling. Nobody has modeled the ratchet colliding with a recorded maximum-secured- amount; I flag it as a new defect the fix creates. AMBIGUOUS.

Net: the fix is legally correct (I do not oppose it) and commercially neutral-to-negative for the insurance-capital exit the product needs.

FX-B. Hold-to-organic-exit restructuring (my own Stage 1 fix (ii)) — the

investor's FX-2/DC-10 challenge: CONCEDED on viability.

The investor is right that a 25-30-year vehicle returning 5.7-9.9% gross has no LP category, and that an evergreen variant requires NAV marks that cannot exist before the secondary market does (their FX-2). I concede DC-10 resolves in their favor: my fix (ii) is a truth-in-fundraising requirement, not a viability repair — its expected effect is that the fund does not raise. I restate it accordingly: honest hold-to-maturity documentation is mandatory if the sponsor proceeds, and its predictable commercial consequence is the investor's Stage 1 verdict. The duration does not disappear under restructuring; it moves onto LPs who cannot hold it — which is a transfer, not a fix.

FX-C. Licensed-carrier Equity Shield (sec-cf Verdict pt. 3, option (a)):

insurable in form, uninsurable at the budgeted price — and partially

uninsurable at any price.

Pricing a real carrier (or captive) on the actual peril: expected loss 0.3-0.8%/yr (incl. the discharge channel at baseline), capital sized to a 1-in-200 correlated housing tail at 8-12% of insured deployed capital, 10% cost of capital, plus expense load:

Capital EL/yr Required premium
8% 0.3% ~140 bps
8% 0.8% ~190 bps
12% 0.3% ~180 bps
12% 0.8% ~230 bps

Versus the 50-75 bps the product budgets. At an honest ~200 bps the marketed investor return goes 8.5% → ~6.3-6.5% (the sponsor's own panel shows 75 bps already costs 0.7pp). The consumer of the guarantee cannot afford the guarantee. Two further problems: (i) the monoline financial guarantors that wrote correlated housing-tail risk pre-2008 (Ambac, MBIA, FGIC) were destroyed by it, and no post-2008 monoline writes novel housing-price floors — there is no willing carrier at any price near feasibility (industry- practice observation, not law); (ii) the Chapter 7 discharge channel is elective and non-fortuitous (R2) — a carrier would exclude it, meaning the "licensed" Shield would not cover the loss channel that SETTLED LAW makes the largest. The fix produces a lawful product that is either unaffordable or hollow. Sec-cf's option (b) — an LP-owned first-loss tranche with offering- document treatment — remains the only structurally honest path, at the $6-12M day-one sizing from my 1.3.

FX-D. Honest ratchet repricing to 4-5 pp/yr (my own Stage 1 breakeven):

the consumer product does not survive it. Reaffirmed with numbers.

Repricing the ratchet to the ~4pp/yr my duration math requires, homeowner side (12-year hold, standard deal):

HPA Share at yr 12 Owed at exit APR-equivalent
3%, current 1pp (30%) 30% $205,830 6.3%
3%, honest 4pp (45%) 45% $245,745 8.5%
5%, current 1pp (30%) 30% $275,223 9.9%
5%, honest 4pp (45%) 45% $349,835 12.9%
20-yr hold at the 50% cap, 5% 50% $642,656 10.5%

At 4pp/yr the homeowner hits the 50% cap by year ~13; every cell of retail's V-table moves into or past HELOC-dominated territory; retail's C3/P1 ratchet findings and sec-cf's 3.3 deception analysis all worsen; and tax D-3 (time-based accrual = interest) strengthens — the investor's FX-8 and I agree the structure cannot buy duration compensation without buying debt characterization. My Stage 1 5.1 conclusion stands: open-ended duration cannot be compensated on the appreciation-share axis at any consumer-defensible speed. Any reviewer's fix list that includes "reprice the ratchet honestly" is prescribing a consumer product with a 10-13% APR- equivalent and a 50% appreciation cession — i.e., prescribing the kill.

FX-E. Pause reform and hardship provisions (operator 1.4/3.1 fixes;

red-team M1; estate fix 4 medical carve-out): consumer-mandatory,

actuarially adverse — and they invalidate my own early-cycle math.

I concur with the investor's FX-6 that this is a design contradiction, and I add the two actuarial mechanisms:

  • Term extension for paused months re-deploys committed capital into homes with demonstrated drawdown, later in time — antiselection of capital into the weakest collateral. It also destroys the early-cycle loss limiter my Finding 1.2 relied on: with extension, deployed-at-trough rises from ~$7.5K/deal toward $45K+/deal for peak vintages, floor breaches rise per the R1 vintage table, and the Shield/first-loss sizing must rise again. My 1.2's "the floor is not breached early-cycle" conclusion is contingent on the pause operating exactly as the consumer reviewers say it must not.
  • Hardship carve-outs and medical occupancy exceptions select the longest, weakest exits into the retained book: forbearance on settlement is duration extension concentrated in the tail, and my 4.2 shows each year of extension destroys 8-10% of position PV. A homeowner-elective suspension (which the Medicaid problem in estate 2.4(a) effectively requires) also makes total consideration homeowner-path-dependent — deepening the variable-consideration defect tax P-5 identifies. LIKELY INTERPRETATION (adopting tax's frame).

There is no parameterization that is simultaneously non-abusive to the homeowner and loss-limiting to the fund. I join the investor in moving this from the fix list to the kill list.

FX-F. Escrowed / LC-backed committed capital (estate fix 6): doubles the

insured exposure the Shield or first-loss reserve must cover.

The investor's FX-5 covers the fund-economics damage (staged deployment was the one real innovation). The insurance-domain addition: full day-one funding means a peak-vintage correction hits ~100% of committed capital deployed instead of the staged ~15-50%. Floor exposure in the R1 stress roughly doubles; the honest first-loss sizing (my 1.3: 6-12% of deployed) doubles in dollars with it; and the LC provider — a bank writing a 50-150bps standby on a startup fund's 84-month consumer obligations — will itself require the capital the structure lacks. The homeowner-protection fix and the guarantee-solvency fix draw on the same missing capital.

FX-G. The honest-disclosure stack (retail verdict minimum bar; sec-cf

gating items): antiselection re-sizes every reserve upward.

Adopting the investor's FX-3 mechanism (honest disclosure removes HELOC-eligible prospects; the residual book is the no-alternative population): the residual book carries higher senior-delinquency, foreclosure, and — post-roadmap — discharge hazard. In my corrected decomposition (R2), that moves normal-decade expected loss toward the top of the 2-4.5%-of-deployed range before any tail event, which means any Shield successor or LP first-loss tranche sized on the pre-disclosure book is undersized on the post-disclosure book. Disclosure quality and reserve adequacy move inversely: a fact that must be priced into any "fixed" launch, and is priced into none of the panel's fix lists.

================================================================================

DIRECT CONFLICTS

DC-A. Me (Stage 1 1.1/Verdict) vs. Investor crossexam (Dispute 1). Actuarial: "distressed sales almost never breach the floor; robust even at −45%." Investor: 0.17x recovery on spec parameters. Incompatible because both cannot describe the same waterfall at the same drawdown. Resolved by concession in R1 — the investor is right at sand-state severity; my claim survives only to a −27.1% breakeven.

DC-B. Me (Stage 1 loss decomposition) vs. Estate 4.1 / Red-team M4. Foreclosure-only floor loss vs. a SETTLED-LAW sale-independent discharge channel. Incompatible loss models; the Shield sizing and any Tier 2 price depend on which is right, and estate's is settled law. Resolved by concession in R2.

DC-C. Sec-cf (Verdict pt. 1: incumbents operate under "materially similar characterization risk"; core salvageable) vs. Tax (A-2: strictly worse-positioned; the defects ARE the product) vs. Title (1.2: the 1.0x floor fails the CFPB Roberts loss-sharing test more cleanly than products already condemned). Incompatible baseline-risk premises; my D4 adds that the salvage also fails on buyer-side capital arithmetic even where the law is fixed.

DC-D. Operator (verdict: monthly deployment, ride-along, ratchet "genuinely better-designed"; fixable for $4-7M) vs. Tax (verdict: those same features destroy the characterization and must be deleted). The features the operator would fund are the features the tax reviewer requires removed. Both cannot be right about the same clauses; my D6 adds that even the operator's fixed machine produces assets with no buyer.

DC-E. Estate + Title ("record a true lien") vs. Tax D-1/D-4 + Sec-cf 3.2 (lien + recharacterization detonates TILA/usury/arbitration) — the central conflict of the file, as the investor also flagged (their DC-4). My FX-A adds a third leg: the lien fix does not even deliver the insurance-capital benefit its proponents assume (Schedule BA treatment unchanged; phantom- income problem created).

DC-F. Me (Stage 1 fix (ii): honest hold-to-maturity vehicle) vs. Investor (C1/C4/B5, crossexam FX-2/DC-10: that vehicle is the kill scenario, not the fix). Incompatible viability judgments over the identical restructuring. Resolved: I concede on viability (FX-B) — the fix stands only as a disclosure obligation.

DC-G. Sec-cf (Verdict pt. 3, option (a): Equity Shield can exist as a policy written by a licensed carrier) vs. my solvency arithmetic (1.1, 1.3, FX-C: required premium 140-230bps vs. 50-75 budgeted; discharge channel non-fortuitous and excluded; no willing carrier). A legal fix and an actuarial impossibility pointed at the same product: licensing changes who is insolvent, not whether the risk is fundable at the offered fee.

DC-H. Retail (T4: escrow waterfall "LIKELY INTERPRETATION as enforceable") vs. Title (2.2: priority order contradicted by SETTLED closing practice, unenforceable against non-parties). Title's is the informed tag — and my corrected recovery model (R1) inherits title's caveat: my escrow figures assume an enforceable senior-to-costs claim that title shows no closing will honor, so my 0.17-1.03x recoveries are upper bounds. (The investor's DC-1 made the adjacent point; I record my model's dependence on it.)

DC-I. Retail P7 / Red-team H7 ("insurers will buy and price off mortality/mobility tables") vs. my 4.1/4.4 + 3.1 (no credible mobility tables; no insurer clears RBC). The predation-by-insurer narrative and the no-insurer-buyer finding cannot both stand as written; the supportable version is red-team M2's orphaned-holder weaponization (my D5).

DC-J. Operator 4.1 (break-even needs 6,000-8,000 positions / $750M-1B) vs. Sec-cf 2.3 (ICA owner caps; Advisers Act exemption dies past $150M) vs. my 3.3 (no institutional LPs before seasoning that cannot exist on schedule). The scale operations require is the scale the legal structure and LP market cannot deliver. (Concurring with the investor's DC-9.)

DC-K. Red-team C2 (incumbent monthly-draw wrapper "strictly dominant") vs. Investor crossexam Dispute 4 + my 3.2 (dominance is purchased with rated-securitization cost of capital, not free in the wrapper). I side with the investor: my 3.2 is the mechanism they cite, and the honest version of C2 still carries red-team's conclusion.

DC-L. Operator 4.1 (credits a 1.5-2% management fee) vs. Investor O1/A15/B5 (no fee stack exists in the spec; the same undefined fees cannot fund the platform and deliver the marketed LP return). Accounting conflict (investor's DC-12); it matters in my domain because any reserve-funding or carrier-premium pro forma must name which pocket pays — and there is no pocket.

DC-M. Me (Stage 1 1.2: the pause freezes deployment, so early-cycle floor losses are contained) vs. Operator 1.4 / Red-team F1-M1 / Retail T9 (the pause as specified is the product's chief consumer-harm engine and must be reformed). Direct conflict between my loss containment and their mandatory reforms: every consumer-fair pause reform (buffers, hysteresis, term extension, forfeiture teeth) increases deployed-at-trough and re-opens the early-cycle floor exposure my 1.2 said was contained (FX-E). The pause cannot simultaneously be the fund's credit-risk limiter and a fair consumer term. (Concurring with and extending the investor's FX-6.)

================================================================================

REVISED POSITION AFTER CROSS-EXAMINATION

Stage 1 verdict was FIX-BEFORE-LAUNCH with two embedded kills (Equity Shield; the year-7-8 Tier 2 exit). After cross-examination:

  1. Both embedded kills are stronger. Corrected reserve coverage in the design-case tail: 0.29-0.33x (was 0.47x). Corrected fee-to-expected-loss: ~1.5-4.5x (was 6-18x) — the Shield is less overpriced than I said only because the product is riskier than I said. The discharge channel is uninsurable in principle, defeating even the licensed-carrier rebuild.
  2. My principal pro-product mitigation is withdrawn. The core contract's escrow recovery is robust only to a −27% national-scale drawdown; at concentrated/sand-state severity, sale exits are a second ~full-severity loss channel. The "core contract need not be killed" reasoning in my Stage 1 verdict no longer rests on recovery robustness; what remains of it rests only on the homeowner-contract's insurance-classification defensibility (my 2.3), which is untouched.
  3. On fund-level financeability I now concur with the investor: the honest restructurings (hold-to-maturity, honest ratchet, real risk transfer, disclosure stack) each price the product at zero demand in my domain's markets. My fix-before-launch verdict therefore describes a product that, fixed, does not fund — which is a kill implemented as a fix list. I retain FIX-BEFORE-LAUNCH formally for the homeowner-side contract mechanics (my lane's remaining survivable component) and record that at the fund and platform level the panel's kill consensus is, on my corrected numbers, arithmetically right.

--- end of cross-examination ---